OLMA
NASDAQ · Biotechnology
Olema Pharmaceuticals Inc
$14.08
-0.88 (-5.88%)
Open$14.96
Previous Close$14.96
Day High$15.01
Day Low$14.04
52W High$36.26
52W Low$2.86
Volume—
Avg Volume3.04M
Market Cap1.30B
P/E Ratio—
EPS$-1.86
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+19.4% upside
Current
$14.08
$14.08
Target
$16.81
$16.81
$15.48
$16.81 avg
$21.94
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 273.28M | 252.57M | 215.43M |
| Net Income | -27,842,007 | -24,319,116 | -27,608,347 |
| Profit Margin | -10.2% | -9.6% | -12.8% |
| EBITDA | -48,708,771 | -44,721,101 | -36,525,999 |
| Free Cash Flow | -19,743,741 | -20,820,819 | -13,833,937 |
| Rev Growth | +22.4% | +21.1% | -4.4% |
| Debt/Equity | 0.25 | 0.24 | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |